Light Sciences Limited Partnership

Light Sciences Corporation

Light Sciences Oncology Inc.

Purdue Pharmaceutical Products L.p.

Singletto Inc.

Other

Euro-celtique S.a.

James C Chen

Brent Wiscombe

Darrin Huston

Brian D Wilkerson

Steven Ross Daly

David J Brown

Llew Keltner

Zihong Guo

David Bartholomew Shine

Jeffrey R Storm

William Louis Barnard

Jonathan S Dahm

Phillip Burwell

Kathleen Lendvay

Celesta Jane Bjornson

John David Bjornson

LuAnn Lawton Chen

Stephanie Marie Chong-Ming Chen

Daniel Duong Hoang

Paul Deven Rolley

Charles Michael McQuade

Elric W Saaski

Gregory Lee Heacock

Gary Lichttenegger

Hugh Narciso

Frank Zheng

Jennifer Kristine Matson

Nick Yeo

Nicholas Yeo

Brian D Swanson

Thomas Wenger

Jean Bishop

Joseph M Hobbs

Erik Hagstrom

Jay Winship

Gregory L Heacock

S Erik Hagstrom

Jeffrey Robin Storm

A method of manufacture and a fabric product that includes a concentrated formulation of photosensitizers having anti-microbial properties that are applied to outer surfaces of the fabric product. The inner surfaces of the fabric product are configured as a protective barrier for a user of the fabric product. Light activation of the photosensitizers protects the user against a range of pathogens, toxins, poisons, microbial particles and radiation particles incident on the outer surfaces of the fabric product.

Skin protection against microbial particles

A photosensitizer formulation can be disposed on or in a mesh; net; netting; screen; curtain of strands, fibers, or monofilaments; substrate, personal protective gear, mask, or any other suitable object. The photosensitizer formulation, when in contact with molecular oxygen and activated by light or ultrasound, produces microbicidal singlet oxygen. A variety of different arrangements and applications are described. For example, an air flow device may also be included to generate a flow of air through or over the photosensitizer formulation. A fluorescent formulation may be included to monitor photobleaching. The photosensitizer formulation may be disposed in a concentration gradient to generate antigenic particles by damaging or destroying microbes.

Microbial disinfection for personal protection equipment

A light transmission system to provide photodynamic treatment to a patient includes a single use integrated control module and catheter assembly having a plurality of light emitting diodes (LEDs) to transmit light toward target cells within a patient. The integrated light catheter and control module are used in combination with a light activated drug. Selected operating parameters may be programmed into the control module, or it may be wirelessly programmable in situ prior to use to allow user flexibility to tailor treatment for a particular patient or condition. Among the features that prevent reuse are that the control module lacks access to recharge the power source, and it may include a deactivation module that destroys circuitry or software when triggered. To prevent patient interference when in use, the control module may also be configured to selectively deactivate.

Light transmission system for photoreactive therapy

A prostate treatment system having a light delivery device positionable in a transurethral device for treatment of benign prostatic hyperplasia (BPH). The light delivery device includes light generator, such as light emitting diodes (LED), laser diodes (LDs) or a diffusion quartz fiber tip connected to a light generator or a light emitting polymer which produces light at a selected wavelength or waveband or alternative sources of suitable light energy. The treatment device may further include a temperature monitoring system for monitoring the temperature at the treatment site. A light-activated drug is administered to the treatment site prior to light activation. The light-activated drug therapy induces cell death of the target tissue. The device provides a minimally invasive transurethral method for treatment of BPH or prostate cancer.

Method and apparatus for light-activated drug therapy

A light delivery system to provide light treatment to a patient includes a catheter assembly having a plurality of light sources that transmit light towards a target site within a patient. In one embodiment, the light delivery system has a plurality of light sources mounted to a flexible transparent base that extends at least partially through a distal tip of the catheter assembly. The light sources can be wire bonded or mounted in a flip chip arrangement onto the base. In one embodiment to produce the distal tip, an array of light energy sources can be held by an array of holders of a fixture device. A vacuum is applied to secure each light energy source in a corresponding holder. While the vacuum is applied, the energy sources are electrically connected by wire bonding. The vacuum can be reduced or stopped thereby permitting removal of the light energy sources from the fixture device.

Light delivery system

An energy treatment system to treat a patient includes an energy delivery device having a plurality of energy emitters used in combination with an energy activatable drug. A mask can be used to define a treatment area. Energy from the energy emitters passes through an optical window of the mask to activate a cosmetically and/or therapeutically effective amount of the activatable drug at the target site to bring about a desired change of tissue, for example, to reduce visibility of one or more blood vessels, while energy from the energy emitters directed outside of the target site is blocked by the mask.

Non-invasive vascular treatment systems, devices, and methods of using the same

A method of manufacture and medical apparatus that provides an apparatus useful in illuminating at least a portion of a lumen of a body. The apparatus includes an elongated flexible member and a polymer encasement portion encasing a plurality of light emitters. The light emitters may be electrically coupled to one another without the use of wire bonds, and in some embodiments may be coupled without intervening electrical paths or traces. A maximum cross-sectional dimension of the polymer encasement portion may be less than twice a dimension of one of the light emitters. In some embodiments the maximum cross-sectional dimension is less than or equal to the sum of the dimension of one of the light emitters and a marginal dimension by which an outer portion of the polymer encasement portion extends beyond the light emitter. Light emitters may be arranged linearly, helically or in partially overlapping back-to-back relation.

Medical apparatus employing flexible light structures

The efficacy of light activated therapy treatment is enhanced by stimulating the immune system of the patient substantially above a normal level. Abnormal tissue that is destroyed by the light activated therapy releases factors that stimulate the immune system, leading to systemic reductions in abnormal tissue (i.e., reduction beyond the region treated using light). By further stimulating the immune system using an anti-CTLA-4 antibody, the systemic destruction of abnormal tissue is enhanced.

Enhancement of light activated therapy by immune augmentation using anti-CTLA-4 antibody

The present invention provides a prophylactic light activated treatment method for subjects at risk of a plaque-mediated thrombotic event, such as acute coronary syndromes. In one embodiment, the subject receives a dose of photosensitizer sufficient to result in a concentration of photosensitizer in the neovascularization associated with atherosclerotic disease to permit effective photodynamic therapy. Light of a wavelength that excites the photosensitizer, but that does not to any significant extent penetrate to an adventitial layer of the blood vessel, is applied to the region of the blood vessel. The therapeutic light dose, which may be applied in sequential stages, is sufficient to cause closure of neovasculature leakage and lead to plaque stabilization and reduced adverse clinical outcomes. The present invention further provides light transmission devices and systems useful in carrying out the methods of the present invention.

Photoreactive system and methods for prophylactic treatment of atherosclerosis

This invention discloses methods, kits, and instructions to treat neovasculature diseases of the eye through the administration of a targeted photosensitizing agent and subsequent exposure to light of specific wavelength sufficient to photoactivate photosensitizing agent. The photosensitizing agent is bound to a composition that mediates site specific delivery to a neovasculature target tissue of a therapeutically effective amount of a photosensitizing agent that is activated by a relatively low fluence rate of light over a prolonged period of time. Diseases treatable under this invention, include: diabetic retinopathy; macular degeneration; and malignant uveal melanomas.

Photodynamic therapy treatment for eye disease

Growing community of inventors

Bellevue, WA, United States of America

James C Chen